The Company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of … Kite’s most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA). Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors (CAR-T).. During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other B-cells expressing a specific antigen. Some of the content on this page is not intended for users outside the US.

3 Q1’20 representation of program phase based on criteria used by Forty Seven.

Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline. You will receive a link to create a new password via email. 3 Combination of cilofexor FXR agonist and firsocostat ACC inhibitor (selonsertib no longer included). Please enter your username or email address. Phase 1. © 2020 Gilead Sciences, Inc. All rights reserved. Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. 1 European Commission Conditional Marketing Approval and US Emergency Use Authorization granted. Senators on Trial Diversity, Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study, Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir, Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims, Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China, Gilead Sciences Response to Médecins Sans Frontières, Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation, Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak, Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials, Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents, Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV), Gilead Statement on Commitment to Advancing Descovy for PrEP™ Study in Cisgender Women & Adolescent Females, Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents, Petitions to US Patent and Trademark Office on HIV PrEP Patents, Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy. For the latest updates on our ongoing response to COVID-19, please click here. Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. DLBCL - Diffuse large B-cell lymphoma. MCL - Mantle cell lymphoma. Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated.